Government-Owned Inventions; Availability for Licensing: Human Antibodies With Anti-Lymphocyte Specificities and Lytic Activity
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH under HHS, announces availability for licensing of a government-owned invention: human antibodies derived from a patient with idiopathic CD4 lymphocytopenia (ICL). These antibodies target and kill B cells and T cells, showing potent lytic activity against B-cell tumors and normal immune cells. One standout antibody, NIH58.9, eliminates B cells at ultra-low concentrations of 0.01 nanomolar, offering advantages over animal-derived antibodies that risk immune rejection. Developed using advanced genetic sequencing of patient plasma, these fully human IgM antibodies can be used directly, engineered into IgG1 formats, bispecific antibodies, or antibody-drug conjugates. Potential applications include therapies for B-cell lymphomas, autoimmune diseases like lupus and multiple sclerosis, and organ transplantation. The technology is at the pre-clinical stage, with U.S. Provisional Patent Application 63/787,190 filed April 11, 2025 (HHS Reference E-025-2025). Licensing follows 35 U.S.C. 209 and 37 CFR part 404, with contacts via Benjamin Hurley (240-276-5489, benjamin.hurley@nih.gov). A Confidential Disclosure Agreement is required for unpublished details. NIAID also seeks collaborators for further development.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Invention HHS Ref. E-025-2025 available for licensing under 35 U.S.C. 209 and 37 CFR part 404
- U.S. Provisional Patent 63/787,190 filed April 11, 2025
- NIH58.9 antibody kills B cells at 0.01 nM concentration
+ 3 more changes with Pro
Obligations
What this law requires
Prospective licensees must execute a signed Confidential Disclosure Agreement (CDA) prior to receiving copies of unpublished information related to the invention
Licensees must comply with 35 U.S.C. 209 and 37 CFR part 404 when licensing this government-owned invention
All licensing inquiries and requests must reference HHS Reference No. E-025-2025 when contacting the Technology Transfer and Intellectual Property Office
Parties interested in collaborative research must submit statements of capability or interest to the NIAID Technology Transfer office
Commercial development of the antibody therapies must be conducted in accordance with applicable U.S. patent law and provisional patent application 63/787,190 filed April 11, 2025